Andrew Neil Charles Weir
Algemeen Directeur bij Sitryx Therapeutics Ltd.
Oorsprong van het eerstegraads netwerk van Andrew Neil Charles Weir
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom.
10
| Holding Company | Medical Specialties | 10 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Andrew Neil Charles Weir via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Founder Corporate Officer/Principal | |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor Private Equity Investor | |
| TOUCHSTONE INNOVATIONS PLC | Investment Managers | Corporate Officer/Principal | |
| SYNDAX PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Semprae Laboratories, Inc.
 Semprae Laboratories, Inc. Medical/Nursing ServicesHealth Services Semprae Laboratories, Inc. provides consumer products for female sexual health. The company was founded by Rachel Braun Scherl and Mary Wallace Jaensch in 2008 and is headquartered in San Diego, CA. | Medical/Nursing Services | Chairman | |
| POXEL | Pharmaceuticals: Major | Chairman | |
| IXICO PLC | Miscellaneous Commercial Services | Director/Board Member | |
| SPYRE THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Imperial College London | College/University | Doctorate Degree | |
| University of Cambridge | College/University | Undergraduate Degree Graduate Degree | |
| The University of Texas at Austin | College/University | Undergraduate Degree | |
| University of California San Diego | College/University | Corporate Officer/Principal | |
| University of Amsterdam | College/University | Corporate Officer/Principal | |
| Vrije Universiteit Amsterdam | College/University | Doctorate Degree | |
| HEC Montréal | College/University | Undergraduate Degree | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Touchstone Innovations Investment Management Ltd.
 Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Director/Board Member | |
Molecular Vision Ltd.
 Molecular Vision Ltd. Medical SpecialtiesHealth Technology Molecular Vision Ltd. develops low-cost, lab-quality, point of care, disposable diagnostic devices for medical testing. The company was founded by Donal D. C. Bradley in 2001 and is headquartered in York, the United Kingdom. | Medical Specialties | Director/Board Member | |
| Chimeric Therapies, Inc. | Corporate Officer/Principal | ||
Kuur Therapeutics Ltd.
 Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Touchstone Innovations Businesses LLP
 Touchstone Innovations Businesses LLP Investment ManagersFinance Touchstone Innovations Businesses LLP commercializes academic research and technology businesses. The company was founded on December 19, 2007 and is headquartered in London, the United Kingdom. | Investment Managers | Corporate Officer/Principal | |
Eckerd Corp.
 Eckerd Corp. Drugstore ChainsRetail Trade Part of Rite Aid Corp., Eckerd Corp. is a company that owns and operates drugstores. The company is based in Largo, FL. | Drugstore Chains | Chief Executive Officer | |
| BICYCLE THERAPEUTICS PLC | Biotechnology | Director/Board Member Chairman | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member | |
Autifony Therapeutics Ltd.
 Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Sanofi-Aventis Groupe SA
 Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Sanofi-Aventis Groupe SA operates as a holding company, with interest in the manufacture and distribution of pharmaceutical products. The company was founded on December 19, 1995 and is headquartered in Paris, France. | Financial Conglomerates | Chief Executive Officer | |
Topivert Pharma Ltd.
 Topivert Pharma Ltd. Pharmaceuticals: MajorHealth Technology Topivert Pharma Ltd. is a British pharmaceutical company founded in 2011. The private company develops non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal. | Pharmaceuticals: Major | Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| ARMO BIOSCIENCES INC | Pharmaceuticals: Major | Director/Board Member | |
| CLEMENTIA PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Chairman | |
Kesios Therapeutics Ltd.
 Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Galvani Bioelectronics Ltd.
 Galvani Bioelectronics Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Galvani Bioelectronics Ltd. is a pioneering research and British development company founded in 2016, dedicated to bringing bioelectronic therapies to patients. The company is based in Stevenage, UK. Galvani Bioelectronics combines GSK's therapeutics discovery and development knowledge with Verily's expertise in software and electronics for clinical applications. The company is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through the use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy. | Pharmaceuticals: Major | Director/Board Member | |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Director/Board Member | |
| Stone Sunny Isles, Inc. | Chief Executive Officer | ||
| UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member | |
BicycleTx Ltd.
 BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Egle Therapeutics SAS
 Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Miscellaneous Commercial Services | Chairman | |
| ADYNXX, INC. | Pharmaceuticals: Major | Director/Board Member | |
Bicycle Therapeutics, Inc.
 Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | Pharmaceuticals: Major | Chairman |
Statistieken
Internationaal
| Verenigd Koninkrijk | 23 |
| Verenigde Staten | 18 |
| Frankrijk | 5 |
| Nederland | 3 |
| Canada | 3 |
Sectoraal
| Health Technology | 28 |
| Consumer Services | 10 |
| Finance | 6 |
| Commercial Services | 4 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 89 |
| Corporate Officer/Principal | 27 |
| Founder | 18 |
| Chairman | 16 |
| Independent Dir/Board Member | 12 |
Sterkste connecties
| Insiders | |
|---|---|
| Pierre Legault | 45 |
| Richard H. Aldrich | 31 |
| Kate Bingham | 31 |
| Maina Bhaman | 26 |
| Paul-Peter Tak | 15 |
| Ravi Rao | 10 |
| Iain Kilty | 8 |
| Jonathan Powell | 1 |
| Jeff Rathmell | 1 |
| Michael Rosenblum | 1 |
- Beurs
- Insiders
- Andrew Neil Charles Weir
- Bedrijfsconnecties
